At Gena, our mission has always been clear: to empower cancer patients and their loved ones through innovative, patient-centred technology. Today, we’re thrilled to announce that Gena has been accepted into Digital Health Center Bülach and Tenity’s Digital Health Accelerator in Zurich – a program renowned for supporting cutting-edge startups transforming healthcare globally.
This opportunity places us alongside some of the most innovative startups in the digital healthcare space from across Europe, empowering us to further revolutionise cancer care for patients and their families.
What Is Tenity’s Digital Health Accelerator?
Tenity (formerly F10) is a globally recognised VC and start-up accelerator dedicated to driving innovation in the financial and health technology sectors. Its Digital Health Accelerator program supports groundbreaking startups, offering them the resources, mentorship, and connections needed to scale and thrive. Focused on digital healthcare, this Zurich-based program is a hub for innovation, bringing together global healthcare leaders, investors, and experts to transform healthcare delivery.
Tenity’s Digital Health Accelerator program is a comprehensive initiative designed to boost the growth and success of early-stage digital health startups. The program offers a wide range of benefits, including access to experienced mentors, potential investors, structured training, and valuable resources such as office space and cutting-edge resources. Startups accepted into the program also gain credibility, visibility, and networking opportunities within a vibrant ecosystem of entrepreneurs, industry experts, and potential partners
You can learn more about the program here.
Why This Matters to Us
Joining Tenity isn’t just an accolade; it’s a pivotal step in our journey to reshape how patients navigate cancer care. For too long, the healthcare system has struggled to keep pace with the needs of rare cancer patients, leaving them with limited treatment options and even fewer answers. At Gena, we’re tackling these gaps head-on by creating tools that put patients at the centre of their care – and Tenity’s program is the perfect launchpad to bring our vision to life on a global stage.
The program’s focus on areas such as marketing, patient engagement, data aggregation, and solutions for chronic diseases aligns well with the digital health space, offering Gena Health tailored guidance and opportunities to enhance its offerings
Being part of this prestigious accelerator represents a significant step forward for Gena and our mission to improve the lives of cancer patients and their carers.
What We’re Excited About
Being part of Tenity means accessing an incredible ecosystem of mentors, investors, and innovators. Over the next few months, we’ll be refining our technology, scaling our impact, and learning from the best in digital health. For us, this isn’t just about networking – it’s about making meaningful strides in how cancer patients access and understand their treatment options.
The program’s focus on innovation and collaboration perfectly aligns with our goals, from advancing genomic sequencing accessibility to designing intuitive digital interfaces that empower patients with the provision of personalised treatment options. Tenity’s emphasis on supporting healthcare startups with real-world impact underscores the value of what we’re building at Gena.
What’s Next?
Stay tuned as we embark on this exciting chapter with Tenity and DHC. From expanding our reach to collaborating with other inspiring startups, this is just the beginning.
Here’s to pushing the boundaries of what’s possible in cancer care – one innovation at a time.
If you want you want to find out more, please contact us here.
Skomer founded Gena after his mother passed away from Glioblastoma, a devastating brain cancer. As her caregiver and a cancer researcher, he witnessed the severe limitations in treating rare cancers.
Thus, Gena was born. Gena’s mission is to give cancer patients access to all available personalised treatment pathways. Informing better treatment decisions. Empowering cancer patients.
Skomer previously worked in the tech sector, responsible for building scaling teams. He completed his MSc at UCL’s School of Engineering in 2022, having written his dissertation on the applications of genomics within the health sector and beyond.
